Agonists And Antagonists Of The Human Complement C3a Receptor
Funder
National Health and Medical Research Council
Funding Amount
$473,250.00
Summary
Many serious inflammatory diseases, such as arthritis, septic shock, lung shock, heart disease, atherosclerosis, multiple sclerosis, are poorly controlled with currently available drugs. There is a great deal of evidence that naturally occuring Complement proteins in human blood are involved in exacerbating these and many other human diseases, yet there are no good drugs available to counteract their effects. One of the most important complement proteins is known as C3a. It is called an anaphyla ....Many serious inflammatory diseases, such as arthritis, septic shock, lung shock, heart disease, atherosclerosis, multiple sclerosis, are poorly controlled with currently available drugs. There is a great deal of evidence that naturally occuring Complement proteins in human blood are involved in exacerbating these and many other human diseases, yet there are no good drugs available to counteract their effects. One of the most important complement proteins is known as C3a. It is called an anaphylatoxin and is thought to be a pivotal component of the complement system synthesized by the human body early on in the development of inflammatory and immune diseases. New compounds that could stimulate or block the activity of C3a are expected : (a) To lead us to a better understanding of how C3a binds to its receptors on immune cells and its role in the immune response to infection and injury, and (b) To enable the rapid development of an entirely new class of drugs for treating autoimmune and inflammatory diseases. No Complement-based drugs are yet available. It is not yet possible to examine detailed structures of the receptors on cells that interact with complement proteins. However it is possible to determine and analyse three dimensional structures of small molecules that can bind to human immune cells, and mimic or block effects of human C3a on cells, rat tissues, and in whole rats. We will identify and improve such small molecules by optimising their binding to immune cells, by tailoring them to selectively block or mimic just the effects of C3a, and by making them pharmacologically stable for administration (preferably by mouth) to rats (and humans). We will then test them in rats for potential future development into a completely new type of anti-inflammatory drug, one that treats inflammatory disease processes rather than just the symptoms like most current antiinflammatory drugs.Read moreRead less
Peroxisome Proliferator Activated Receptor Gamma Is A Novel Therapeutic Target For Inflammation And Remodelling In Asthma
Funder
National Health and Medical Research Council
Funding Amount
$307,436.00
Summary
Asthma affects over 2 million Australians with 300 deaths each year. Current drugs are not always effective. A new approach is to reduce the thickening and stiffening of the airway muscle found in asthma. Rosiglitazone, an antidiabetic drug in current use, inhibits growth of airway muscle in the test tube and chest tightening in a mouse model of asthma. Cells from asthmatics will be used to confirm these positive findings, and to support rapid clinical evaluation of this drug to benefit patients ....Asthma affects over 2 million Australians with 300 deaths each year. Current drugs are not always effective. A new approach is to reduce the thickening and stiffening of the airway muscle found in asthma. Rosiglitazone, an antidiabetic drug in current use, inhibits growth of airway muscle in the test tube and chest tightening in a mouse model of asthma. Cells from asthmatics will be used to confirm these positive findings, and to support rapid clinical evaluation of this drug to benefit patients.Read moreRead less
Potential Roles Of 5-hydroxytryptamine In Diseases Affecting The Colon
Funder
National Health and Medical Research Council
Funding Amount
$346,018.00
Summary
The overall aim of this project is to examine the biological roles played by 5-hydroxytryptamine (5-HT) in the human colon. 5-HT is a naturally occurring substance of the body, normally involved in controlling many body activities. Relevance is placed in this project on the possibility that 5-HT is involved in causing or contributing to certain clinical conditions, either by excess or deficiency. The conditions that are the focus of this project are chronic constipation, diverticular disease and ....The overall aim of this project is to examine the biological roles played by 5-hydroxytryptamine (5-HT) in the human colon. 5-HT is a naturally occurring substance of the body, normally involved in controlling many body activities. Relevance is placed in this project on the possibility that 5-HT is involved in causing or contributing to certain clinical conditions, either by excess or deficiency. The conditions that are the focus of this project are chronic constipation, diverticular disease and irritable bowel syndrome. It is a matter of concern that there are no specific treatments for these conditions to date, hence the thrust of the project is to increase knowledge in this area, so hopefully treatments will be developed. Our Pharmacology research group is recognised for its experience in defining drug effects on the intestine and in characterising the target sites on which they act. This has been achieved by using an integrated approach whereby different functional methods reliably detect effects at the levels of the muscle layers, the nerves that supply them and at the absorptive surface using experimental animals. In addition, the use of isolated pieces of human colon obtained from discarded operation material has been an invaluable inclusion into this process. This has allowed us to establish that 5-HT has a target site in the muscle of the colon and that this leads to relaxation and inhibition of the normal spontaneous contractile activity, said anecdotally to be abnormally high in patients with irritable bowel syndrome. We now wish to apply this expertise and knowledge to test whether 5-HT is involved in causing chronic constipation and diverticular disease and to design a drug that would be expected to be of value in treating patients with irritable bowel syndrome.Read moreRead less